Claims
- 1. Compound of the formula I ##STR11## in which n denotes 0 or 1, m denotes 1 or 2, but (n+m).ltoreq.2,
- A together with the bridgehead carbon atoms denotes a benzene or a cyclohexane ring,
- Y.sub.1 denotes hydrogen, (C.sub.1 -C.sub.6)-alkanoyl or (C.sub.5 -C.sub.8)-cycloalkanoyl, benzoyl or a radical of the formula II, ##STR12## or, if A is part of a benzene ring then Y.sub.1 is as defined 20 above or denotes nicotinoyl, and
- Y.sub.2 denotes amino, (C.sub.1 -C.sub.6)-alkanoylamino, (C.sub.5 -C.sub.8)-cycloalkanoylamino or benzoylamino,
- or, if A is part of a benzene ring then Y.sub.2 is as defined above or denotes nicotinoylamino.
- 2. The compound defined in claim 1 wherein n is 0 and m is 1.
- 3. The compound defined in claim 1 wherein n is 0 and m is 2.
- 4. The compound defined in claim 1 wherein m and n are 1.
- 5. The compound defined in claim 1 wherein m and n are 1 and Y.sub.2 is amino, (C.sub.1 -C.sub.6)-alkanoylamino, (C.sub.5 -C.sub.8)-cycloalkanoylamino, benzoylamino or nicotinoylamino.
- 6. The compound defined in claim 1 wherein A is part of a benzene ring.
- 7. The compound defined in claim 1 wherein A is part of a cyclohexane ring.
- 8. A compound as in claim 1 which is N-acetyl-S-benzoyl-D-cysteinyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
- 9. A compound as in claim 1 which is N-D-cysteinyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
- 10. A compound as in claim 1 which is N-acetyl-D-cysteinyl-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
- 11. A compound as in claim 1 which is N-D-cysteinyl-L-decahydroisoquinoline-3-carboxylic acid.
- 12. A compound as in claim 1 which is N-acetyl-S-benzoyl-D-cysteinyl-L-decahydroisoquinoline-3-carboxylic acid.
- 13. A compound as in claim 1 which is N-acetyl-D-cysteinyl-L-decahydroisoquinoline-3-carboxylic acid.
- 14. A method for treating hypertension which comprises administering to a patient afflicted with hypertension a hypotensively effective amount of a compound as in claim 1.
- 15. A composition comprising a hypotensively effective amount of a compound as claimed in claim 1 and a pharmaceutically acceptable carrier compounds.
Priority Claims (3)
Number |
Date |
Country |
Kind |
2937779 |
Sep 1979 |
DEX |
|
2946909 |
Nov 1979 |
DEX |
|
3044236 |
Nov 1980 |
DEX |
|
Parent Case Info
This application is a continuation-in-part application of U.S. application Ser. No. 520,227 filed Aug. 5, 1983, which is a continuation application of U.S. application Ser. No. 188,228 filed Sept. 17, 1980, and of U.S. application 534,392 filed Sept. 22, 1983, which is a continuation application of U.S. application Ser. No. 324,141 filed Nov. 23, 1981, all now abandoned.
US Referenced Citations (15)
Foreign Referenced Citations (9)
Number |
Date |
Country |
5472780 |
Aug 1980 |
AUX |
6141780 |
Feb 1981 |
AUX |
6512380 |
Jun 1981 |
AUX |
0012845 |
Jul 1980 |
EPX |
0018104 |
Oct 1980 |
EPX |
0050800 |
Jun 1982 |
EPX |
2443533 |
Sep 1980 |
FRX |
2042535 |
Sep 1980 |
GBX |
2048863 |
Dec 1980 |
GBX |
Related Publications (1)
|
Number |
Date |
Country |
|
534392 |
Sep 1983 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
188228 |
Sep 1980 |
|
Parent |
324141 |
Nov 1981 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
520227 |
Aug 1983 |
|